BMC Geriatrics (Jul 2024)

Physical enhancement of older adults using hyperbaric oxygen: a randomized controlled trial

  • Amir Hadanny,
  • Efrat Sasson,
  • Laurian Copel,
  • Malka Daniel-Kotovsky,
  • Eldad Yaakobi,
  • Erez Lang,
  • Gregory Fishlev,
  • Nir Polak,
  • Mony Friedman,
  • Keren Doenyas,
  • Shachar Finci,
  • Yonatan Zemel,
  • Yair Bechor,
  • Shai Efrati

DOI
https://doi.org/10.1186/s12877-024-05146-3
Journal volume & issue
Vol. 24, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Introduction Aging is associated with a progressive decline in the capacity for physical activity. The objective of the current study was to evaluate the effect of an intermittent hyperbaric oxygen therapy (HBOT) protocol on maximal physical performance and cardiac perfusion in sedentary older adults. Methods A randomized controlled clinical trial randomized 63 adults (> 64yrs) either to HBOT (n = 30) or control arms (n = 33) for three months. Primary endpoint included the maximal oxygen consumption (VO2Max) and VO2Max/Kg, on an E100 cycle ergometer. Secondary endpoints included cardiac perfusion, evaluated by magnetic resonance imaging and pulmonary function. The HBOT protocol comprised of 60 sessions administered on a daily basis, for 12 consecutive weeks, breathing 100% oxygen at 2 absolute atmospheres (ATA) for 90 min with 5-minute air breaks every 20 min. Results Following HBOT, improvements were observed in VO2Max/kg, with a significant increase of 1.91 ± 3.29 ml/kg/min indicated by a net effect size of 0.455 (p = 0.0034). Additionally, oxygen consumption measured at the first ventilatory threshold (VO2VT1) showed a significant increase by 160.03 ± 155.35 ml/min (p < 0.001) with a net effect size of 0.617. Furthermore, both cardiac blood flow (MBF) and cardiac blood volume (MBV) exhibited significant increases when compared to the control group. The net effect size for MBF was large at 0.797 (p = 0.008), while the net effect size for MBV was even larger at 0.896 (p = 0.009). Conclusion The findings of the study indicate that HBOT has the potential to improve physical performance in aging adults. The enhancements observed encompass improvements in key factors including VO2Max, and VO2VT1. An important mechanism contributing to these improvements is the heightened cardiac perfusion induced by HBOT. Trial registration ClinicalTrials.gov Identifier NCT02790541 (registration date 06/06/2016).

Keywords